Eli Lilly reported that its selective RET kinase inhibitor selpercatinib (Retevmo) achieved a statistically significant improvement in investigator‑assessed event‑free survival in the Phase 3 LIBRETTO‑432 trial, which enrolled 151 patients with early‑stage (II–IIIA) RET‑fusion‑positive non‑small cell lung cancer. The study is the first and only randomized Phase 3 trial to evaluate selpercatinib as adjuvant therapy after definitive surgery or radiotherapy, and it met its primary endpoint by reducing the risk of disease recurrence or death. Overall survival data trended favorably, although the results are still immature.
The outcome represents a strategic expansion of Lilly’s oncology portfolio beyond its existing CAR‑T and small‑molecule programs. By demonstrating efficacy in the adjuvant setting, Retevmo could become the first‑in‑class treatment for a rare subset of lung cancer patients, opening a new revenue avenue as the company moves toward regulatory submission. The trial also underscores Lilly’s commitment to precision oncology and the importance of genomic testing to identify patients who can benefit from targeted therapies.
Jacob Van Naarden, president of Lilly Oncology, said the results confirm that “cancer medicines can deliver their greatest impact when administered early in the course of a patient’s treatment journey.” He added that the LIBRETTO‑432 data “support this observation, demonstrating an effect size in line with the most striking data for targeted adjuvant therapy in lung cancer,” and that the findings should accelerate the use of genomic testing for all early‑stage patients.
In the broader therapeutic landscape, Retevmo is already approved for advanced RET‑altered NSCLC, and other RET inhibitors such as pralsetinib are available for metastatic disease. The LIBRETTO‑432 results position selpercatinib as a unique option in the adjuvant setting, potentially capturing a market that currently lacks targeted therapies for early‑stage RET‑fusion‑positive disease.
While specific financial impact and regulatory timelines are not yet disclosed, the trial’s success is expected to strengthen Lilly’s pipeline and support future growth in its oncology segment. The company’s ongoing focus on genomic testing and precision medicine is likely to enhance its competitive positioning and drive long‑term value creation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.